NASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free AVIR Stock Alerts $3.70 -0.01 (-0.27%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$3.68▼$3.7650-Day Range$3.70▼$4.5652-Week Range$2.77▼$5.19Volume267,758 shsAverage Volume436,377 shsMarket Capitalization$311.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atea Pharmaceuticals alerts: Email Address Atea Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$327,852 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.76) to ($2.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.50 out of 5 starsMedical Sector873rd out of 918 stocksPharmaceutical Preparations Industry381st out of 402 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Atea Pharmaceuticals. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.26% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atea Pharmaceuticals has recently decreased by 1.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVIR. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for AVIR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $327,852.00 in company stock.Percentage Held by Insiders14.50% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atea Pharmaceuticals are expected to decrease in the coming year, from ($2.76) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Atea Pharmaceuticals Stock (NASDAQ:AVIR)Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Read More AVIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVIR Stock News HeadlinesMarch 27, 2024 | globenewswire.comAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsMarch 21, 2024 | edition.cnn.comAtea Pharmaceuticals, Inc.April 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereMarch 16, 2024 | finance.yahoo.comAVIR Apr 2024 2.500 callMarch 3, 2024 | finance.yahoo.comAVIR Mar 2024 7.500 callMarch 1, 2024 | markets.businessinsider.comAtea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory RisksMarch 1, 2024 | finanznachrichten.deAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | finance.yahoo.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call TranscriptApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereFebruary 28, 2024 | benzinga.comRecap: Atea Pharmaceuticals Q4 EarningsFebruary 28, 2024 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 21, 2024 | finance.yahoo.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024February 21, 2024 | globenewswire.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024February 13, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the FirmJanuary 10, 2024 | finance.yahoo.comAtea Pharma (AVIR) Gains on Upbeat Initial Data From HCV StudyJanuary 9, 2024 | msn.comAtea Pharmaceuticals' Hepatitis C Virus Candidate Shows EfficacyJanuary 9, 2024 | msn.comAtea gains after mid-stage data for lead asset in Hepatitis CJanuary 8, 2024 | finance.yahoo.comAtea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19January 6, 2024 | morningstar.comAtea Pharmaceuticals Inc Ordinary SharesJanuary 6, 2024 | morningstar.comAtea Pharmaceuticals Inc Ordinary SharesJanuary 3, 2024 | finance.yahoo.comAtea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNovember 13, 2023 | finance.yahoo.comAtea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023November 9, 2023 | finance.yahoo.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Atea Pharmaceuticals Inc Earnings CallNovember 8, 2023 | msn.comAtea Pharmaceuticals GAAP EPS of -$0.40November 8, 2023 | finance.yahoo.comAtea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateSee More Headlines Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVIR CUSIPN/A CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees75Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.07% Return on Assets-22.04% Debt Debt-to-Equity RatioN/A Current Ratio18.24 Quick Ratio18.24 Sales & Book Value Annual Sales$351.37 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value$6.65 per share Price / Book0.56Miscellaneous Outstanding Shares84,170,000Free Float71,961,000Market Cap$311.43 million OptionableOptionable Beta0.16 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Jean-Pierre Sommadossi Ph.D. (Age 68)Founder, Chairman, CEO & President Comp: $1.1MMs. Andrea J. Corcoran J.D. (Age 62)CFO, Executive VP of Legal & Secretary Comp: $732.45kMr. John F. Vavricka (Age 60)Chief Commercial Officer Comp: $581.11kDr. Janet M. J. Hammond M.D. (Age 63)Ph.D., Chief Development Officer Comp: $817.16kDr. Maria Arantxa Horga M.D. (Age 55)Chief Medical Officer Comp: $695.85kMr. Wayne Foster CPA (Age 55)Executive VP of Finance & Chief Accounting Officer Ms. Jonae R. BarnesSenior Vice President of Investor Relations & Corporate CommunicationsMr. Ariyapadi N. KrishnarajVice President of MarketingMr. Adel Moussa Ph.D.Executive Vice President of ChemistryMr. Xiao-Jian Zhou Ph.D.Executive Vice President of Early Stage DevelopmentMore ExecutivesKey CompetitorsEnanta PharmaceuticalsNASDAQ:ENTATerns PharmaceuticalsNASDAQ:TERNESSA PharmaNASDAQ:EPIXInozyme PharmaNASDAQ:INZYNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 26,270 shares on 3/11/2024Ownership: 5.465%Goldman Sachs Group Inc.Sold 32,183 shares on 3/1/2024Ownership: 0.274%Sunpointe LLCBought 11,943 shares on 2/20/2024Ownership: 0.014%GSA Capital Partners LLPSold 128,408 shares on 2/16/2024Ownership: 0.180%Price T Rowe Associates Inc. MDBought 12,927 shares on 2/16/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions AVIR Stock Analysis - Frequently Asked Questions Should I buy or sell Atea Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVIR shares. View AVIR analyst ratings or view top-rated stocks. How have AVIR shares performed in 2024? Atea Pharmaceuticals' stock was trading at $3.05 at the beginning of 2024. Since then, AVIR stock has increased by 21.3% and is now trading at $3.70. View the best growth stocks for 2024 here. When is Atea Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AVIR earnings forecast. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) released its earnings results on Wednesday, February, 28th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03. What ETFs hold Atea Pharmaceuticals' stock? ETFs with the largest weight of Atea Pharmaceuticals (NASDAQ:AVIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM).iShares U.S. Pharmaceuticals ETF (IHE). When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVIR) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeBiden replacement revealed?Paradigm PressThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.